Organogenesis Holdings Inc. (ORGO): Entry into a Material Definitive Agreement
Organogenesis Holdings Inc. (ORGO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d117484dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 ORGANOGENESIS HOLDINGS INC. UP TO $75,000,000 OF CLASS A COMMON STOCK (par value $0.0001 per share) AT-THE-MARKET SALES AGREEMENT August 6, 2026 BTIG, LLC 65 East 55th Street New York, NY 10022 Citizens JMP Securities, LLC 1301
How this was made
The 30-second read
Why it matters
The disclosed up to $75M ATM capacity creates a potential dilution overhang, but the actual market impact depends on how much is sold, at what prices, and whether proceeds fund value-accretive initiatives.
Market read
A fresh SEC filing discloses new equity issuance capacity via an ATM program, which can drive near-term trading via dilution expectations.
What to watch
Traders should watch whether the company actually sells shares soon, the average sale price versus recent trading levels, and any concurrent guidance or cash-use disclosures not included in the excerpt.
Background
The 8-K reports entry into an at-the-market (ATM) sales agreement with BTIG and Citizens JMP Securities, tied to a shelf registration statement.
Ticker impact
Organogenesis entered a material definitive agreement for an at-the-market sales program up to $75M of Class A common stock.
Bias to downside or higher volatility around execution/placement activity, especially if sales begin immediately.
ATM programs are typically dilutive over time; the filing specifies up to $75M capacity but does not state timing or actual shares sold yet, limiting precision on magnitude.
Market effects
Adds to the broader read-through that smaller healthcare issuers may use ATM programs for liquidity, which can weigh on peer sentiment during equity issuance windows.
Primarily US small/mid-cap healthcare equity sentiment.
Limited global impact; mostly company-specific financing mechanics.
Counterpoint
If the ATM is used opportunistically at favorable prices, it can reduce balance-sheet risk without a large one-time discount, limiting long-term damage.
Key entities
- issuerOrganogenesis Holdings Inc.
Subject of the 8-K, entering an ATM sales agreement for Class A common stock.
- agentBTIG, LLC
One of the sales agents under the ATM agreement.
- agentCitizens JMP Securities, LLC
Co-agent under the ATM agreement.
